OncoCyte
OncoCyte is a biotechnology company focused on developing and commercializing novel, non-invasive liquid biopsy diagnostics for early cancer detection. Established in 2009, the company aims to provide actionable answers to physicians and patients along the lung cancer care continuum, optimizing diagnosis, treatment, and improving patient outcomes while reducing healthcare costs.
Top Stages
1 past transactions
Chronix Biomedical
Acquisition in 2021
Chronix Biomedical, Inc. is a molecular diagnostics company specializing in the development of laboratory-developed blood tests, known as liquid biopsy tests, for cancer and organ transplant monitoring. Founded in 1997 and headquartered in San Jose, California, the company has established laboratories in Brookings, South Dakota, and Göttingen, Germany. Chronix's products include the CNI Monitor, which assesses the effectiveness of cancer therapies, and the Transplant Monitor, designed to detect organ rejection by quantifying transplant-specific DNA in plasma. The company employs proprietary technology to analyze circulating nucleic acids, allowing for the diagnosis and management of chronic diseases and cancer. Chronix aims to partner with various organizations to expand its DNA-based assays, which have the potential to improve the management of a wide range of cancers and other health conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.